Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, marking a 17.1% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Is now the time to buy Supernus Pharmaceuticals, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it’s free.
Why Is Supernus Pharmaceuticals Not Exciting?
We’re happy investors have made money, but we don't have much confidence in Supernus Pharmaceuticals. Here are three reasons you should be careful with SUPN and a stock we'd rather own.
1. Long-Term Revenue Growth Disappoints
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Supernus Pharmaceuticals grew its sales at a mediocre 5.6% compounded annual growth rate. This fell short of our benchmark for the healthcare sector.
2. Fewer Distribution Channels Limit its Ceiling
Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.
With just $719 million in revenue over the past 12 months, Supernus Pharmaceuticals is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.
3. Free Cash Flow Margin Dropping
Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
As you can see below, Supernus Pharmaceuticals’s margin dropped by 14.5 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. Supernus Pharmaceuticals’s free cash flow margin for the trailing 12 months was 6.4%.
Final Judgment
Supernus Pharmaceuticals’s business quality ultimately falls short of our standards. With its shares topping the market in recent months, the stock trades at 22.8× forward P/E (or $53.23 per share). This multiple tells us a lot of good news is priced in - you can find more timely opportunities elsewhere. We’d suggest looking at a top digital advertising platform riding the creator economy.
Stocks We Would Buy Instead of Supernus Pharmaceuticals
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
